OKUR (OnKure Therapeutics) Debt-to-Asset : 0.01 (As of Dec. 2024)

View and export this data going back to 2024. Start your Free Trial

What is OnKure Therapeutics Debt-to-Asset?

OnKure Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.54 Mil. OnKure Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $0.55 Mil. OnKure Therapeutics's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $114.91 Mil. OnKure Therapeutics's debt to asset for the quarter that ended in Dec. 2024 was 0.01.

OnKure Therapeutics Debt-to-Asset Historical Data

The historical data trend for OnKure Therapeutics's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OnKure Therapeutics Debt-to-Asset Chart

OnKure Therapeutics Annual Data

Trend

Dec22

Dec23

Dec24

Debt-to-Asset

0.04

0.02

0.01

OnKure Therapeutics Quarterly Data
	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial				0.02	0.03	0.25	0.01	0.01

Competitive Comparison of OnKure Therapeutics's Debt-to-Asset

For the Biotechnology subindustry, OnKure Therapeutics's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OnKure Therapeutics's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OnKure Therapeutics's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where OnKure Therapeutics's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

OnKure Therapeutics Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

OnKure Therapeutics's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.536	+	0.549)	/	114.907
	=	0.01

OnKure Therapeutics's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0.536	+	0.549)	/	114.907
	=	0.01

OnKure Therapeutics (NAS:OKUR) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

OnKure Therapeutics Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of OnKure Therapeutics's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

OnKure Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OnKure Therapeutics Inc (NAS:OKUR) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

6707 Winchester Circle, Suite 400, Boulder, CO, USA, 80301

Website

https://www.onkuretherapeutics.com

OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. The company operates in one operating segment which is clinical research. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.